Article info
PDFOriginal research
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
- Correspondence to Dr Joe Yeong, Pathology, Singapore General Hospital, Singapore 169856, Singapore; joe.yeong.p.s{at}sgh.com.sg; Professor Puay Hoon Tan; tan.puay.hoon{at}singhealth.com.sg
Citation
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
Publication history
- Received October 6, 2019
- Revised December 23, 2019
- Accepted December 31, 2019
- First published January 22, 2020.
Online issue publication
August 19, 2020
Article Versions
- Previous version (19 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.